We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients.
- Authors
Bohanec Grabar, Petra; Rozman, Blaž; Tomšič, Matija; Šuput, Daša; Logar, Dušan; Dolžan, Vita
- Abstract
Leflunomide is a disease-modifying antirheumatic drug used for treating rheumatoid arthritis (RA). In vitro studies demonstrated that cytochromes P450 (CYPs), mainly CYP1A2 and CYP2C19, might be involved in leflunomide activation. The aim of our study was to investigate whether genetic polymorphisms of CYP1A2, CYP2C19, and CYP2C9 influence leflunomide toxicity. A genotyping approach was used to determine CYP1A2*1F, CYP2C19*2, CYP2C19*17, CYP2C9*2, and CYP2C9*3 alleles in 105 RA patients. Leflunomide treatment was well tolerated by 62 patients, whereas 43 patients discontinued the treatment within the first year due to toxicity. Patients with CYP1A2*1F CC genotype had a 9.7-fold higher risk for overall leflunomide-induced toxicity than did the carriers of CYP1A2*1F A allele [ P = 0.002, odds ratio = 9.708, 95% confidence interval = 2.276–41.403]. No significant association between the CYP2C19 and CYP2C9 genotypes and the leflunomide toxicity was observed. Our results suggest that the CYP1A2*1F allele may be associated with leflunomide toxicity in RA patients.
- Subjects
LEFLUNOMIDE; IMMUNOSUPPRESSIVE agents; RHEUMATOID arthritis; AUTOIMMUNE diseases; CYTOCHROME P-450; GENETIC polymorphisms; IMMUNOLOGIC diseases; BLOOD hyperviscosity syndrome; ADDISON'S disease
- Publication
European Journal of Clinical Pharmacology, 2008, Vol 64, Issue 9, p871
- ISSN
0031-6970
- Publication type
Article
- DOI
10.1007/s00228-008-0498-2